Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00729690 · ClinicalTrials.gov registry record · Phase 3

Effect of Oral Pregabalin on Spinal Neurotransmitters in Patients Undergoing Knee Replacement

A Phase 3 study, sponsored by Asokumar Buvanendran.

Completed
Registry status
Phase 3
Development phase
48
Enrollment target

NCT00729690: Completed Phase 3 study, sponsored by Asokumar Buvanendran.

NCT00729690 is a Phase 3 study that has completed, run by Asokumar Buvanendran. The registered enrollment target is 48 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00729690, a Phase 3 study, has completed, sponsored by Asokumar Buvanendran.

COMPLETED
Registry status
Phase 3
Development phase
48 participants
Enrollment target

Study Summary

This study involves research. Pregabalin is a Food and Drug Administration (FDA) medication approved in the United States for the treatment of nerve pain related to diabetes and post-herpetic neuralgia "shingles", and for seizures in adults. The purpose of this research is to study the effect of oral Pregabalin on spinal neurotransmitters in subjects undergoing Total Knee Replacement Surgery (TKA). TKA is associated with considerable postoperative pain which if unrelieved may result in prolonged hospital stay, inability to participate in rehabilitation programs, poor outcomes, and greater use of health-care resources. This study examines the effect of pregabalin administered for TKA on pain-related neurotransmitter concentrations.

Primary Outcome

Numerical Response scale NRS(0-10) Pain scores were collected every 4 hours after the initial dose and the Area Under the Curve (AUC) calculated. Calculated for the 1st 24 hours after initial dose (0-24hr). AUC measured in NRS pain score points per hour (NRS\*hr). Larger AUC values indicate higher levels of reported pain.

Interventions

  • DRUG Placebo
  • DRUG Pregabalin

Trial Details

FieldValue
Enrollment Target 48 participants
Start Date 2008-08
Est. Completion 2011-07
Phase Phase 3
Asokumar Buvanendran

3 total trials

What the finished NCT00729690 record still lists

NCT00729690 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (94% lower).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT00729690 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00729690 about?

NCT00729690 is a clinical study titled "Effect of Oral Pregabalin on Spinal Neurotransmitters in Patients Undergoing Knee Replacement". This study involves research. Pregabalin is a Food and Drug Administration (FDA) medication approved in the United States for the treatment of nerve pain related to diabetes and post-herpetic neuralgia "shingles", and for seizures in adults. The purpose of this research is to study the effect of ora...

What is the current status of trial NCT00729690?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 48 participants. The study started on 2008-08. Estimated completion is 2011-07.

What interventions are being tested in trial NCT00729690?

The interventions under investigation include: Placebo (DRUG), Pregabalin (DRUG).

Who is sponsoring clinical trial NCT00729690?

This trial is sponsored by Asokumar Buvanendran, which has 3 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00729690's enrollment target sits among peer trials

48 1862nd of 2000 higher than 134 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01765777 · 48 participants · NA

    Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain

  • NCT03073343 · 48 participants · NA

    A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine

  • NCT03431064 · 48 participants

    Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients

  • NCT03514602 · 48 participants · NA

    Maternal Smoking Cessation and Pediatric Obesity Prevention

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00729690, the US trial registry maintained by the National Library of Medicine. NCT00729690 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.